NCT02658487: A reported trial by Vanderbilt-Ingram Cancer Center
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02658487 |
|---|---|
| Title | Phase II Trial of Vosaroxin in Combination With Infusional Cytarabine in Patients With Untreated AML |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | March 31, 2016 |
| Completion date | April 30, 2019 |
| Required reporting date | April 29, 2020, midnight |
| Actual reporting date | April 30, 2020 |
| Date last checked at ClinicalTrials.gov | Dec. 3, 2025 |
| Days late | None |